NEBIVOLOL- nebivolol tablet Bandaríkin - enska - NLM (National Library of Medicine)

nebivolol- nebivolol tablet

amerigen pharmaceuticals inc. - nebivolol hydrochloride (unii: jgs34j7l9i) (nebivolol - unii:030y90569u) - nebivolol 2.5 mg - nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see clinical studies (14.1) ]. nebivolol tablets may be used alone or in combination with other antihypertensive agents [see drug interactions (7) ]. lowering blood pressure reduces the risk of fatal and non fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nebivolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, su

None 20 mcg/mL Suspension for Injection(IM) (Multidose) (Adult) Filippseyjar - enska - FDA (Food And Drug Administration)

none 20 mcg/ml suspension for injection(im) (multidose) (adult)

n/a; importer: genpharm inc.; distributor: genpharm inc. - hepatitis b vaccine (rdna) - suspension for injection(im) (multidose) (adult) - 20 mcg/ml

Lotor 500mg Film Coated Tablet Filippseyjar - enska - FDA (Food And Drug Administration)

lotor 500mg film coated tablet

n/a; importer: genpharm, inc.; distributor: genpharm, inc. - levofloxacin (as hemihydrate) - film coated tablet - 500mg

None Lyophilized Powder for Injection (SC) Filippseyjar - enska - FDA (Food And Drug Administration)

none lyophilized powder for injection (sc)

n/a; importer: genpharm, inc.; distributor: genpharm, inc. - measles, mumps and rubella vaccine (live, attenuated) - lyophilized powder for injection (sc) - formulation each dose (0.5 ml) contains: measles virus (edmonston-zagreb strain)....nlt 1000 ccid50 mumps virus (leningrad-zagreb strain).......nlt 5000 ccid 50 rubella virus (wistar ra 27/3 strain)..nlt 1000 ccid 50

Tresivac Freeze-dried Powder for Suspension for Injection (SC) Filippseyjar - enska - FDA (Food And Drug Administration)

tresivac freeze-dried powder for suspension for injection (sc)

n/a; importer: genpharm, inc.; distributor: genpharm, inc. - measles, mumps and rubella vaccine (live, attenuated) - freeze-dried powder for suspension for injection (sc) - formulation: after reconstitution, one dose (0.5 ml) contains: measles virus-nlt 1,000 ccid 50 mumps virus-nlt 5,000 ccid 50 rubella virus -nlt 1,000 ccid 50

FLUOXETINE- fluoxetine hydrochloride capsule Bandaríkin - enska - NLM (National Library of Medicine)

fluoxetine- fluoxetine hydrochloride capsule

sciegen pharmaceuticals, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 10 mg - fluoxetine is indicated for the treatment of: - acute and maintenance treatment of major depressive disorder [see clinical studies (14.1)] . - acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd) [see clinical studies (14.2)] . - acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe bulimia nervosa [see clinical studies (14.3)] . - acute treatment of panic disorder, with or without agoraphobia [see clinical studies (14.4)] . fluoxetine and olanzapine in combination is indicated for the treatment of: - acute treatment of depressive episodes associated with bipolar i disorder. - treatment resistant depression (major depressive disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). fluoxetine monotherapy is not indicated for th

OMEPRAZOLE AND SODIUM BICARBONATE capsule Bandaríkin - enska - NLM (National Library of Medicine)

omeprazole and sodium bicarbonate capsule

sciegen pharmaceuticals, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 20 mg - omeprazole and sodium bicarbonate capsules are indicated in adults for the: - short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. - short-term treatment (4 to 8 weeks) of active benign gastric ulcer. - treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. - short-term treatment (4 to 8 weeks) of ee due to acid-mediated gerd which has been diagnosed by endoscopy in adults. the efficacy of omeprazole and sodium bicarbonate used for longer than 8 weeks in patients with ee has not been established. if a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. if there is recurrence of ee or gerd symptoms (e.g., heartburn), additional 4 to 8-week courses of omeprazole and sodium bicarbonate may be considered. - the efficacy of omeprazole and sodium bicarbonate used for longer than 8 weeks in patients with ee has not been established. if a patie

FLUOXETINE- fluoxetine hydrochloride tablet Bandaríkin - enska - NLM (National Library of Medicine)

fluoxetine- fluoxetine hydrochloride tablet

sciegen pharmaceuticals, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine tablets are indicated for the treatment of: - major depressive disorder (mdd). the efficacy of fluoxetine in mdd was established in one 5-week trial, three 6-week trials, and one maintenance study in adults. the efficacy of fluoxetine was also established in two 8- to 9-week trials in pediatric patients 8 to 18 years of age [see clinical studies (14.1)]. - obsessions and compulsions in patients with obsessive compulsive disorder (ocd). the efficacy of fluoxetine in ocd was demonstrated in two 13-week trials in adults and one 13-week trial in pediatric patients 7 to 17 years of age [see clinical studies (14.2)]. - binge-eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. the efficacy of fluoxetine in bulimia nervosa was demonstrated in two 8-week trials and one 16-week trial in adults [see clinical studies (14.3)]. - panic disorder, with or without agoraphobia. the efficacy of fluoxetine in panic disorder was demonstrated in tw